Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit
San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that they will highlight their collaboration to support the development and manufacturing of Tr1X’s allogeneic Tr1 and CAR-Tr1 Treg cell therapy programs at the 11th Annual CAR-TCR Summit, taking place September 15–17, 2026, in Boston, Massachusetts.
CIRM approves more than $60 million to support clinical and preclinical development awards
South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding of over $40 million for four new preclinical development awards and nearly $21 million to support three clinical trials aimed at testing potential therapies for multiple sclerosis, a form of brain cancer, and a rare genetic disease called […]
Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026
SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease company developing Type 1 regulatory T (Tr1) cell therapies, today announced two oral presentations at the American Society of Gene and Cell Therapy Annual Meeting 2026, May 11-15, 2026, in Boston.
Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD
In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and efficacy
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103
First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional safety, accelerated immune reconstitution, and dose-dependent persistence and induction of Tr1 and FOXP3+ regulatory T cells. All patients achieved successful engraftment and donor chimerism following transplantation.
A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 Cell Infusion in Subjects with Hematological Malignancies Undergoing HLA-Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Use of post-transplant Cyclophosphamide (PTCy) for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) has reduced the incidence of graft versus host disease (GvHD), and expanded donor options for patients to include haploidentical and mismatched unrelated donors. Though PTCy is effective at reducing acute GvHD, 30-40% of patients receiving peripheral blood stem cell (PBSC) grafts […]